CO5200837A1 - VACCINES - Google Patents

VACCINES

Info

Publication number
CO5200837A1
CO5200837A1 CO00072096A CO00072096A CO5200837A1 CO 5200837 A1 CO5200837 A1 CO 5200837A1 CO 00072096 A CO00072096 A CO 00072096A CO 00072096 A CO00072096 A CO 00072096A CO 5200837 A1 CO5200837 A1 CO 5200837A1
Authority
CO
Colombia
Prior art keywords
vaccine
octoxynol
sorbitan ester
antigen
polyoxyethylene sorbitan
Prior art date
Application number
CO00072096A
Other languages
Spanish (es)
Inventor
Martin Friede
Philippe Hermand
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GB0016685A external-priority patent/GB0016685D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5200837A1 publication Critical patent/CO5200837A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

El uso de una combinación de un éster de polioxietilensorbitano y un octoxinol en la preparación de un coadyuvante para aplicación a una superficie mucosa de un paciente.1Un procedimiento para producir una vacuna, comprendiendo el procedimiento mezclar (a) un éster poxietilensorbitano, (b) un octoxinol y (c) un antígeno, y proporcionar la vacuna en forma de una dosis de vacuna para administración en mucosa.1Un dispositivo de pulverización o aerosol, más particularmente un dispositivo de dos dosis, rellenado con una vacuna que comprende un éster de polioxietilensorbitano, un octoxinol y un antígeno.1Un procedimiento para tratar un mamífero que padece o susceptible de una infección patogénica, o cáncer, o alergia, comprendiendo dicho procedimiento la administración a la mucosa del mamífero de una cantidad segura y efectiva de una composición de vacuna que comprende un éster de polioxietilensorbitano, un octoxinol y un antígeno.The use of a combination of a polyoxyethylene sorbitan ester and an octoxynol in the preparation of an adjuvant for application to a mucous surface of a patient.1 A procedure for producing a vaccine, the method comprising mixing (a) a polyethylene sorbitan ester, (b) an octoxynol and (c) an antigen, and providing the vaccine in the form of a vaccine dose for mucosal administration.1 A spray or aerosol device, more particularly a two-dose device, filled with a vaccine comprising a polyoxyethylene sorbitan ester , an octoxynol and an antigen. 1 A procedure for treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, said method comprising administering to the mammal's mucosa a safe and effective amount of a vaccine composition that It comprises a polyoxyethylene sorbitan ester, an octoxynol and an antigen.

CO00072096A 1999-09-24 2000-09-22 VACCINES CO5200837A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GB0016685A GB0016685D0 (en) 2000-07-06 2000-07-06 Novel compounds

Publications (1)

Publication Number Publication Date
CO5200837A1 true CO5200837A1 (en) 2002-09-27

Family

ID=26244613

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00072096A CO5200837A1 (en) 1999-09-24 2000-09-22 VACCINES

Country Status (17)

Country Link
EP (1) EP1221971A2 (en)
JP (1) JP2003509473A (en)
KR (1) KR20020038770A (en)
CN (1) CN1391483A (en)
AU (1) AU765824B2 (en)
BR (1) BR0014282A (en)
CA (1) CA2383413A1 (en)
CO (1) CO5200837A1 (en)
CZ (1) CZ20021043A3 (en)
HK (1) HK1049106A1 (en)
HU (1) HUP0202885A3 (en)
IL (1) IL148672A0 (en)
MX (1) MXPA02003067A (en)
NO (1) NO20021433L (en)
PL (1) PL355163A1 (en)
TR (1) TR200200774T2 (en)
WO (1) WO2001021207A2 (en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283012T3 (en) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. HELICOBACTER PYLORI BACTERIOFERRITINE.
MXPA03003690A (en) 2000-10-27 2004-05-05 Chiron Spa Nucleic acids and proteins from streptococcus groups a b.
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (en) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DK1961426T3 (en) 2003-10-02 2011-08-08 Novartis Ag Combination vaccines against meningitis
DE202005022108U1 (en) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza virus vaccines
RU2379052C2 (en) 2004-04-30 2010-01-20 Чирон С.Р.Л. Meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Immune enhancement compounds
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (en) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101203529A (en) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
DE602006020738D1 (en) 2005-08-01 2011-04-28 Hisamitsu Pharmaceutical Co ADJUVANS OR PHARMACEUTICAL PREPARATION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION
JP2009511636A (en) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Mucosal and systemic immunity with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2420829T3 (en) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vaccines adjuvant with non-virion antigen prepared from influenza viruses grown in cell culture
AU2006310338A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EA015271B1 (en) 2006-01-27 2011-06-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Influenza vaccines containing hemagglutinin and matrix proteins
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
KR20090057015A (en) 2006-09-11 2009-06-03 노파르티스 아게 Making influenza virus vaccines without using eggs
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US20100047327A1 (en) * 2007-01-31 2010-02-25 Tetsuji Kuwahara Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
PL2185191T3 (en) 2007-06-27 2013-02-28 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
PE20110891A1 (en) 2008-12-09 2011-12-23 Pfizer Vaccines Llc IGE CH3 PEPTIDE VACCINE
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
CN102307590A (en) 2009-02-10 2012-01-04 诺华有限公司 Influenza vaccines with reduced amounts of squalene
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
KR101450958B1 (en) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 Pneumococcal vaccine and uses therof
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
MX2012000734A (en) 2009-07-16 2012-01-27 Novartis Ag Detoxified escherichia coli immunogens.
CN102596236B (en) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 Antigenic Tau peptides and uses thereof
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX337070B (en) 2009-12-22 2016-02-11 Celldex Therapeutics Inc Vaccine compositions.
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
ES2910199T3 (en) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Factor H-binding proteins (fHbp) with altered properties and methods of using them
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
HUE043879T2 (en) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Rsv immunization regimen
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
DK3275892T3 (en) 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa PRÆFUSIONS-RSV F ANTIGENS
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PE20142406A1 (en) 2012-05-04 2015-01-23 Pfizer ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
MX2014014067A (en) 2012-05-22 2015-02-04 Novartis Ag Meningococcus serogroup x conjugate.
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
CN105307684A (en) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 Nonlinear saccharide conjugates
JP6266000B2 (en) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
RS56886B1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
JP6114401B2 (en) 2013-10-31 2017-04-12 久光製薬株式会社 Adjuvant composition, adjuvant preparation containing the same, and kit
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
EP4074726A3 (en) 2014-07-23 2022-11-23 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
HRP20230416T1 (en) 2015-01-15 2023-07-07 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
CN108367063A (en) 2015-07-21 2018-08-03 辉瑞公司 Include the immunogenic composition and its kit and purposes of conjugated Capsular saccharide antigen
JP6884145B2 (en) 2015-11-20 2021-06-09 ファイザー・インク Immunogenic composition for use in Streptococcus pneumoniae vaccine
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
MX2019008564A (en) 2017-01-20 2019-09-19 Pfizer Immunogenic compositions for use in pneumococcal vaccines.
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2021132644A (en) 2020-02-21 2021-09-13 ファイザー・インク Purification of saccharide
JP2023514697A (en) 2020-02-23 2023-04-07 ファイザー・インク E. coli composition and method
KR20230096033A (en) 2020-10-27 2023-06-29 화이자 인코포레이티드 Escherichia coli composition and method thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI750929B (en) * 2020-12-02 2021-12-21 林建宏 Temperature-sensitive adjuvant for aerosol immunity and its preparation method
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20220265805A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
EP4333868A1 (en) 2021-05-04 2024-03-13 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202304503A (en) 2021-05-28 2023-02-01 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
NL8403195A (en) * 1984-10-19 1986-05-16 Nederlanden Staat IMMUNOGENIC COMPLEXES AND VACCINES CONTAINING THESE.
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Also Published As

Publication number Publication date
TR200200774T2 (en) 2002-08-21
MXPA02003067A (en) 2002-09-30
BR0014282A (en) 2002-05-21
EP1221971A2 (en) 2002-07-17
AU7907000A (en) 2001-04-24
NO20021433L (en) 2002-05-21
IL148672A0 (en) 2002-09-12
NO20021433D0 (en) 2002-03-21
HUP0202885A3 (en) 2004-07-28
CN1391483A (en) 2003-01-15
WO2001021207A2 (en) 2001-03-29
CZ20021043A3 (en) 2002-08-14
WO2001021207A3 (en) 2001-09-27
PL355163A1 (en) 2004-04-05
HK1049106A1 (en) 2003-05-02
CA2383413A1 (en) 2001-03-29
AU765824B2 (en) 2003-10-02
HUP0202885A2 (en) 2002-12-28
JP2003509473A (en) 2003-03-11
KR20020038770A (en) 2002-05-23

Similar Documents

Publication Publication Date Title
CO5200837A1 (en) VACCINES
AR020050A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AMYLOIDOGENIC DISEASE USE OF AN ABETA PEPTIDE FOR THE PREPARATION OF MEDICINES
BR0108730A (en) System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates
AR005281A1 (en) ORAL PHARACEUTICAL COMPOSITION, PROCEDURES FOR ITS MANUFACTURE AND USE OF THAT PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF MEDICINES. .
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
CO4290346A1 (en) Azithromycin Controlled Release Dosage Forms
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
AR016798A1 (en) USE OF A LACTOBACILLUS CEPA FOR THE PREPARATION OF A MEDICINAL PRODUCT
CR8352A (en) PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
AR032597A1 (en) USE OF ANTIGENS OF THE VIRUS OF THE INACTIVATED FLU, IN THE PREPARATION OF VACCINES OF A SINGLE INTRANASAL DOSE; METHOD FOR THE PROPHYLAXIS OF DISEASES OR OF INFLUENCES IN PATIENTS; EQUIPMENT THAT INCLUDES SUCH VACCINES IN SINGLE DOSE AND METHOD FOR MANUFACTURING VACCINES FOR THE FLU FOR APLI
CY1110376T1 (en) USE OF A COMPOSITION INCLUDING FORMOTEROL AND BUDESONIDE TO PREVENT OR THERAPEUTIC IMMUNITY
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
AR023806A1 (en) USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS
ATE128350T1 (en) PHARMACEUTICAL AEROSOL FORMULATION.
CU23226B7 (en) ANALGESTIC COMPOSITIONS THAT INCLUDE NON-STEROID ANTI-EPILEPTIC AND ANTI-INFLAMMATORY COMPOUNDS
CL2008003938A1 (en) Use of escitalopram or a pharmaceutically acceptable salt thereof to prepare a medicament useful in the treatment of post-traumatic stress disorder (divisional sol. 1799-00).
AR008799A1 (en) VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT
AR033953A1 (en) A FORM OF FREE DRUG IN PARTICLES OF A BETA-CARBOLINE COMPOSITE, ITS PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF SEXUAL DYSFUNCTION, METHOD FOR MANUFACTURING SUCH FORM OF THE COMPOUND AND USE OF PARTICLES
EP1471936A4 (en) Hiv vaccine and method of use
DE69826019D1 (en) SOLID DISPERSING VACCINE COMPOSITION FOR ORAL ADMINISTRATION
AR037524A1 (en) DOSAGE UNIT INCLUDING A PROSTAGLANDINE ANALOG FOR THE CONSTIPATION TREATMENT
CO5540323A2 (en) ORAL ADMINISTRATION OF HORMONE PARATIROIDES AND CALCITONINE
AR008886A1 (en) USE OF AN H +, K + -ATPASE INHIBITOR IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NASAL POLIPS, OF THE WIDAL SYNDROME, USE OF SUCH INHIBITOR AND A GLUCOCORTICOID FOR THE MANUFACTURE OF A PHARMACEUTICAL FORMULATION AND PHARMACEUTICAL FORMULATION
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
CO5241355A1 (en) PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS

Legal Events

Date Code Title Description
FC Application refused